Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The aim of this study was to investigate the colonisation by lactobacilli and clinical outcome in women with bacterial vaginosis (BV) and recurrent vulvovaginal candidiasis (R-VVC) receiving antibiotic or anti-fungal treatment in combination with the probiotic EcoVag® capsules. METHODS: A total of 40 Scandinavian women diagnosed with BV or VVC on the basis of Amsel's criteria or clinical symptoms were consecutively recruited in two pilot open label clinical trials. In trial I, women with BV were treated with clindamycin and metronidazole followed by vaginal EcoVag® capsules, containing Lactobacillus rhamnosus DSM 14870 and Lactobacillus gasseri DSM 14869, for 5 consecutive days after each antibiotic treatment. In trial II, women were recruited in three groups as follows: women with BV receiving clindamycin and metronidazole treatment together with a prolonged administration of EcoVag® (10 consecutive days after each antibiotic treatment followed by weekly administration of capsules for next four months), women with R-VVC receiving extended fluconazole and EcoVag® treatment, and women receiving extended fluconazole treatments only. The difference in frequency of isolation of EcoVag® strains or other lactobacilli between groups was compared by Fisher's exact test. RESULTS: The 6-month cure rate for BV was 50 % in trial I while both the 6- and 12-month cure rates were 67 % in trial II. The 6- and 12-month cure rates for VVC were 100 % and 89 % in women receiving fluconazole and EcoVag®, and 100 % and 70 % in women receiving fluconazole only. The frequency of isolation of any Lactobacillus species during the course of the study was associated with cure of BV in trial I and II, whereas the frequency of isolation of EcoVag® strains was significantly associated with the cure of BV in trial II only. As previously observed, a change in sexual partner was associated with relapse of BV with an Odds ratio of 77 (95 % CI: 2.665 to 2225). CONCLUSIONS: The study suggests that the treatment with antibiotics or anti-fungal medication in combination with EcoVag® capsules provide long-term cure against BV and R-VVC as compared to previous reports. TRIAL REGISTRATION: ClinicalTrials.gov NCT02295579 . Registered November 20, 2014.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis
Sobel, J. D., Wiesenfeld, H. C., Martens, M., Danna, P., Hooton, T. M., Rompalo, A., Sperling, M., Livengood, C., Horowitz, B., Von Thron, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033114 · Cited by 487
Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies
Falagas, M. E., Apostolou, K. E., & Pappas, V. D. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0159-2 · Cited by 294 · cited 1×
“The few clinical studies performed to date regarding supplementation of lactobacilli after conventional antifungal treatment in women with VVC show conflicting results and it is still controversial whether probiotics can prevent recurrences of VVC [19, 30, 44, 45].”
BackgroundFitzsimons, N. A., Cogan, T. M., Condon, S., & Beresford, T. (1999) · Applied and Environmental Microbiology · doi:10.1128/aem.65.8.3418-3426.1999 · Cited by 186 · cited 2×
“T GGGCGTCAA-3’) (primer OPL-2, [28]) for L. gasseri DSM 14869 and RAPD1 (5’-ATGTAACGCC-3’) (primer P2, [29]) and RAPD4 for L. rhamnosus DSM 14870.”
Cited by
Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health
Monteagudo-Mera, A., Rastall, R. A., Gibson, G. R., Charalampopoulos, D., & Chatzifragkou, A. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-09978-7 · Cited by 743
“Numerous evidences have shown that probiotics could be useful for the treatment and prevention of urogenital infections especially in women (Ya et al. 2010; Bisanz et al. 2014; Heczko et al. 2015; Pendharkar et al. 2015).”
BackgroundGuideline: Vulvovaginal Candidosis (AWMF 015/072, Level S2k)
Farr, A., Effendy, I., Frey Tirri, B., Hof, H., Mayser, P., Petricevic, L., Ruhnke, M., Schaller, M., Schaefer, A. P. A., Sustr, V., et al. (2021) · Mycoses · doi:10.1111/myc.13248 · Cited by 184
Morais, I. M. C., Cordeiro, A. L., Teixeira, G. S., Domingues, V. S., Nardi, R. M. D., Monteiro, A. S., Alves, R. J., Siqueira, E. P., & Santos, V. L. (2017) · Microbial Cell Factories · doi:10.1186/s12934-017-0769-7 · Cited by 181
van de Wijgert, J., & Verwijs, M. (2020) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15870 · Cited by 162
Nyirjesy, P., Brookhart, C., Lazenby, G., Schwebke, J., & Sobel, J. D. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1057 · Cited by 149
Metadata
- Authors
- Pendharkar, S., Brandsborg, E., Hammarström, L., Marcotte, H., & Larsson, P.-G.
- Venue
- BMC Infectious Diseases
- Published
- 2015-07-03
- Volume
- 15
- Issue
- 1
- Pages
- 255-255
- ISSN
- 1471-2334 (ISSN-L)
- OpenAlex
- W1517994472
- Cited by
- 96
- References
- 3
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection. https://app.cochat.ai/papers/10.1186/s12879-015-0971-3
- The paper
- Pendharkar, S., Brandsborg, E., Hammarström, L., Marcotte, H., & Larsson, P.-G. (2015). Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection. BMC Infectious Diseases. https://doi.org/10.1186/s12879-015-0971-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.